MA30768B1 - Methodes d'administration d'agents hypoglycemiques a longue duree d'action - Google Patents

Methodes d'administration d'agents hypoglycemiques a longue duree d'action

Info

Publication number
MA30768B1
MA30768B1 MA31741A MA31741A MA30768B1 MA 30768 B1 MA30768 B1 MA 30768B1 MA 31741 A MA31741 A MA 31741A MA 31741 A MA31741 A MA 31741A MA 30768 B1 MA30768 B1 MA 30768B1
Authority
MA
Morocco
Prior art keywords
methods
action
long term
hypoglycemic agents
administering
Prior art date
Application number
MA31741A
Other languages
English (en)
Inventor
Mark A Bush
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA30768B1 publication Critical patent/MA30768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES MÉTHODES ET DES COMPOSITIONS PHARMACEUTIQUES DESTINÉES À L'ADMINISTRATION D'AGENTS HYPOGLYCÉMIQUES ET/OU D'AGONISTES DE GLP-1, CARACTÉRISÉES EN CE QU'ELLES PERMETTENT D'AUGMENTER ET/OU DE MAINTENIR LES VALEURS MOYENNES DE CONCENTRATION PLASMATIQUE MAXIMALE (CMAX) ET/OU DE SURFACE SOUS LA COURBE (AUC) DE L'AGENT HYPOGLYCÉMIQUE.
MA31741A 2006-09-13 2009-03-30 Methodes d'administration d'agents hypoglycemiques a longue duree d'action MA30768B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
MA30768B1 true MA30768B1 (fr) 2009-10-01

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31741A MA30768B1 (fr) 2006-09-13 2009-03-30 Methodes d'administration d'agents hypoglycemiques a longue duree d'action

Country Status (25)

Country Link
US (3) US8338369B2 (fr)
EP (1) EP2073834B1 (fr)
JP (2) JP5524620B2 (fr)
KR (1) KR101472601B1 (fr)
CN (1) CN103705911A (fr)
AR (1) AR062775A1 (fr)
AU (1) AU2007296499C1 (fr)
BR (1) BRPI0716765A8 (fr)
CA (1) CA2662622C (fr)
CL (1) CL2007002634A1 (fr)
CR (1) CR10684A (fr)
EA (1) EA017159B1 (fr)
ES (1) ES2442869T3 (fr)
IL (1) IL197448A (fr)
JO (1) JO2945B1 (fr)
MA (1) MA30768B1 (fr)
MX (1) MX2009002863A (fr)
MY (1) MY149911A (fr)
NO (1) NO20091266L (fr)
NZ (1) NZ575419A (fr)
PE (2) PE20080840A1 (fr)
SG (2) SG174770A1 (fr)
TW (1) TWI430806B (fr)
WO (1) WO2008033888A2 (fr)
ZA (1) ZA200901548B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
DK2373681T3 (en) * 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (fr) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions de peptides glp-1 et leur préparation
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
EP3467106B1 (fr) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Composé peptidique
WO2019149880A1 (fr) 2018-02-02 2019-08-08 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP2186824A3 (fr) * 2000-12-13 2010-09-22 Eli Lilly & Company Posologie de traitement chronique à l'aide de peptides insulinotropiques de type glucagon
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (fr) * 2001-08-23 2003-03-06 Eli Lilly And Company Analogues de glp-1 (glucagon-like peptide 1)
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (fr) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
BR0306706A (pt) * 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
CA2513213C (fr) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
EP1689757B1 (fr) * 2003-11-12 2014-08-27 Phenomix Corporation Composes heterocycliques d'acide boronique
JP4697596B2 (ja) * 2004-01-13 2011-06-08 旭硝子株式会社 多層積層体
JP5010923B2 (ja) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
EP1758575A1 (fr) * 2004-06-11 2007-03-07 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
WO2007139589A1 (fr) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée

Also Published As

Publication number Publication date
TWI430806B (zh) 2014-03-21
BRPI0716765A2 (pt) 2013-09-24
EP2073834A2 (fr) 2009-07-01
EP2073834A4 (fr) 2010-11-03
EA200970274A1 (ru) 2009-08-28
JP2014148524A (ja) 2014-08-21
AR062775A1 (es) 2008-12-03
US20100009910A1 (en) 2010-01-14
SG10201501749WA (en) 2015-05-28
CL2007002634A1 (es) 2008-05-16
CA2662622C (fr) 2017-01-17
PE20121528A1 (es) 2012-12-12
SG174770A1 (en) 2011-10-28
BRPI0716765A8 (pt) 2017-02-21
MX2009002863A (es) 2009-03-30
US20140066371A1 (en) 2014-03-06
MY149911A (en) 2013-10-31
AU2007296499A1 (en) 2008-03-20
CR10684A (es) 2009-04-28
KR20090059155A (ko) 2009-06-10
JP5524620B2 (ja) 2014-06-18
AU2007296499B2 (en) 2013-05-02
WO2008033888A2 (fr) 2008-03-20
CN103705911A (zh) 2014-04-09
ES2442869T3 (es) 2014-02-14
TW200824706A (en) 2008-06-16
PE20080840A1 (es) 2008-08-27
EA017159B1 (ru) 2012-10-30
NZ575419A (en) 2011-11-25
IL197448A0 (en) 2011-08-01
KR101472601B1 (ko) 2014-12-15
NO20091266L (no) 2009-06-09
IL197448A (en) 2013-06-27
EP2073834B1 (fr) 2013-10-23
JP2010503697A (ja) 2010-02-04
US20130005652A1 (en) 2013-01-03
US8338369B2 (en) 2012-12-25
WO2008033888A3 (fr) 2008-10-16
JO2945B1 (en) 2016-03-15
CA2662622A1 (fr) 2008-03-20
JP5753924B2 (ja) 2015-07-22
AU2007296499C1 (en) 2013-09-12
ZA200901548B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
ATE275967T1 (de) Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
CO6440528A2 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico.
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
GT200600004A (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
ECSP088239A (es) Composición de liberación de fármaco sostenida
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
AR043258A1 (es) Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
CL2009000985A1 (es) Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
MX2010005013A (es) Composiciones intranasales.
ECSP088240A (es) Composición de trazodona para administración una vez por día
WO2006089114A3 (fr) Procedes et compositions pour le traitement d'un sujet souffrant d'un etat a mediation assuree par la toxine de l'anthrax
EA200800950A1 (ru) Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
WO2008128191A3 (fr) Formes dosifiees orales de cephalotaxine
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma
AR061155A1 (es) Preparaciones liofilizadas de pantoprazol sodico para inyeccion
WO2007056236A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
CL2008003292A1 (es) Hidrato cristalino de hidrocloruro de r-6-hidroxi-8-{1-hidroxi-2-[2-(4-metoxi-fenil)-1,1-dimetil-etilamino]-etil}-4h-benzo[1,4]oxazin-3-ona; composicion y combinacion farmaceutica que lo comprende; preparacion de una solucion inhalable que lo comprende; y uso en el tratamiento de dolencias respiratorias.